Business
Isodiol International Inc. Reports Fiscal Q1 2019 Financial Results
Isodiol International Inc. Reports Fiscal Q1 2019 Financial Results.
About this update from Isodiol International Inc
[{"type":"text","content":"\nVANCOUVER, British Columbia, Sept. 11, 2018 (GLOBE NEWSWIRE) -- Isodiol International Inc. (CSE: ISOL) (OTCQB: ISOLF) (FSE: LB6A.F) (the “Company” or “Isodiol”),  is proud to announce total first quarter revenue of $9.2 million, representing an approximate 240% increase over the quarter ended June 30, 2017 and an approximate 70% increase over revenues of $5.4 million in the fourth quarter of fiscal 2018.\n FIRST QUARTER HIGHLIGHTS INCLUDE: Total Revenue of $9.2 Million with gross profit of $4.6 millionCash Position of $11.5 millionGovernment Approval from United Kingdom’s Medicines and Healthcare Products Regulatory Agency (MHRA) for Pure, Natural CBD as an Active Pharmaceutical Ingredient (API)Completed Acquisition of KURE Corp and also announced KURE expansion plansBinding Agreement to Acquire 51% of Farmtiva, a cultivator of hemp with operations in CaliforniaBinding Agreement to Acquire 51% of Round Mountain Technologies, a cultivator of hemp with operations in Nevada SUBSEQUENT EVENTS: Introduced Isoderm Direct Effects Technology VIA PBS Television (https://isodiol.com/direct-effects-technology/)Signed LOI with Pure Global Cannabis, for supply of pharmaceutical and nutraceutical CBD isolatesPartnership between ISO-Sport and ALTISExpansion of Kure Retail Stores in Arizona, with the opening of seven locations in the Greater Phoenix marketAnnounced the launch of  ISOCare,  a secure platform for the cannabis treatment industryAnnounced plans to develop new hemp-based beers and functional beveragesAppointed new Chief Financial Officer, Eli DusenburyAppointed Marvin Washington to Board of Directors “The Company is proud to report another significant increase in its revenues,” said CEO of Isodiol, Marcos Agramont. “With regulation in the United States seemingly trending towards a favourable position, the Company believes it is well positioned to capitalize on upcoming opportunities with a variety of distribution channels1.  As we head towards the end of fiscal quarter two and beyond, the Company will continue to focus on building its three core business strategies: Nutraceutical, Pharmaceutical, and Clinical Supply of CBD Ingredients, Contract Manufacturing of Consumer Products Containing CBD ingredients, and Total Vertical Integration of Key Revenue Streams...